Imaging-based Phenotypic Screening is a extremely powerful and flexible approach to drug discovery and pre-clinical research.

Learn how imaging-based phenotypic assays work and what kind of information you can expect from working with us.

LEARN MORE >>>

CAN I COMBINE PHENOTYPIC READOUTS WITH TARGET-CENTRIC READOUTS?

Yes. Phenotypic assays are experiencing a resurgence in popularity within the pharmaceutical and biotech communities but target-centric information remains extremely valuable.

Thankfully, imaging-based assays are well-suited to multiplexing. Multiplexed assays enable us to design a hybrid assay for you that combines functional or “black-box” readouts common to phenotypic assays (e.g. cell viability) with pathway-centric markers such as cleaved caspase that measure apoptosis. Typically, a third marker measuring accumulation and subcellular localization of a kinase target provides the link between phenotypic and target-centric information.

Here is an interesting commentary on PDD and Target-based Drug Discovery (Derek Lowe, Science Translational Medicine 2014) >>>

See what types of phenotypic assays can be performed using imaging-based approaches >>>

Top